|
US9937531B2
(en)
|
2009-03-10 |
2018-04-10 |
Bookit Oy Ajanvarauspalvelu |
Method and system for delivery of goods
|
|
PL372247A1
(en)
|
2002-02-01 |
2005-07-11 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
|
CN100430052C
(zh)
|
2002-03-05 |
2008-11-05 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
WO2003077948A1
(fr)
*
|
2002-03-19 |
2003-09-25 |
Kowa Co., Ltd. |
Myelome : medicaments preventifs/curatifs et methode de diagnostic
|
|
US7414055B2
(en)
|
2003-04-24 |
2008-08-19 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
CN1839114A
(zh)
*
|
2003-08-21 |
2006-09-27 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
CA2535366A1
(en)
*
|
2003-08-27 |
2005-03-10 |
Merck Frosst Canada & Co. |
Cathepsin inhibitors
|
|
PT1663958E
(pt)
*
|
2003-09-18 |
2015-06-01 |
Virobay Inc |
Compostos contendo haloalquilo como inibidores de protease de cisteína
|
|
EP1682524A1
(en)
*
|
2003-10-24 |
2006-07-26 |
Aventis Pharmaceuticals, Inc. |
Novel keto-oxadiazole derivatives as cathepsin inhibitors
|
|
JP2007513890A
(ja)
*
|
2003-12-12 |
2007-05-31 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
|
EP1715920A4
(en)
*
|
2004-01-08 |
2009-03-18 |
Merck Frosst Canada Ltd |
CATHEPSINCYSTEINPROTEASEHEMMER
|
|
US7429674B2
(en)
|
2004-04-14 |
2008-09-30 |
Merck & Co. Inc.. |
Process for preparing fluoroleucine alkyl esters
|
|
CA2575139A1
(en)
|
2004-08-04 |
2006-02-16 |
Merck & Co., Inc. |
Diastereoselective reductive amination process
|
|
WO2006034004A2
(en)
*
|
2004-09-17 |
2006-03-30 |
Schering Aktiengesellschaft |
Processes and intermediates for preparing cysteine protease inhibitors
|
|
TW200619206A
(en)
*
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
AR055283A1
(es)
*
|
2004-11-23 |
2007-08-15 |
Merck Frosst Canada Ltd |
Inhibidores de cisteinproteasa de catepsina
|
|
WO2006060494A1
(en)
|
2004-12-01 |
2006-06-08 |
Schering Aktiengesellschaft |
Haloalkyl containing compounds as cysteine protease inhibitors
|
|
EP1819667B1
(en)
|
2004-12-02 |
2012-10-17 |
ViroBay, Inc. |
Sulfonamide compounds as cysteine protease inhibitors
|
|
EP1841419A4
(en)
*
|
2005-01-19 |
2009-02-25 |
Merck Frosst Canada Ltd |
CATHEPSIN K AND ADIPOSITAS INHIBITORS
|
|
EP1841730A4
(en)
*
|
2005-01-19 |
2010-10-27 |
Merck Frosst Canada Ltd |
CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
|
|
AU2006302797B2
(en)
*
|
2005-03-02 |
2012-02-02 |
Merck Canada Inc. |
Composition for inhibition of cathepsin K
|
|
US20080138635A1
(en)
*
|
2005-03-02 |
2008-06-12 |
Zhikuan Chen |
Conjugated Organic Molecules for Molecular Electronic Devices
|
|
US7488848B2
(en)
*
|
2005-03-21 |
2009-02-10 |
Virobay, Inc. |
Alpha ketoamide compounds as cysteine protease inhibitors
|
|
US7893093B2
(en)
*
|
2005-03-22 |
2011-02-22 |
Virobay, Inc. |
Sulfonyl containing compounds as cysteine protease inhibitors
|
|
JP2008545720A
(ja)
|
2005-06-02 |
2008-12-18 |
メルク フロスト カナダ リミテツド |
カテプシン阻害剤としてのフルオロアルキルアミン誘導体
|
|
JP5311822B2
(ja)
|
2005-07-19 |
2013-10-09 |
第一三共株式会社 |
置換プロパンアミド誘導体及びそれを含む医薬組成物
|
|
BRPI0614169A2
(pt)
*
|
2005-07-26 |
2016-11-22 |
Merck Frosst Canada Ltd |
método para tratar uma doença parasítica, e, composição farmacêutica
|
|
UA100669C2
(ru)
|
2006-06-01 |
2013-01-25 |
Санофі-Авентіс |
Спироциклические нитрилы как ингибиторы протеазы, способ их получения (варианты) и лекарственное средство на их основе
|
|
US7622593B2
(en)
*
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
EP2079683B1
(en)
*
|
2006-10-04 |
2015-01-21 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
US7893112B2
(en)
*
|
2006-10-04 |
2011-02-22 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
AR064693A1
(es)
*
|
2006-12-29 |
2009-04-22 |
Abbott Gmbh & Co Kg |
Compuestos carboxamidas y su utilizacion en la elaboracion de un medicamento para el tratamiento de enfermedades asociadas a alta actividad de calpaina.
|
|
WO2008106059A1
(en)
|
2007-02-26 |
2008-09-04 |
Merck & Co., Inc. |
Formulations for cathepsin k inhibitors
|
|
US8273913B2
(en)
|
2007-04-02 |
2012-09-25 |
Merck Canada Inc. |
Amidation process for the preparation of cathepsin K inhibitors
|
|
WO2008149971A1
(ja)
|
2007-06-08 |
2008-12-11 |
Kyoto University |
脳動脈瘤の治療または予防薬
|
|
US20100331545A1
(en)
|
2007-10-24 |
2010-12-30 |
Nippon Chemiphar Co., Ltd. |
Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
|
|
AU2008329515B2
(en)
*
|
2007-11-29 |
2013-09-05 |
Merck Canada Inc. |
Cysteine protease inhibitors for the treatment of parasitic diseases
|
|
WO2009096198A1
(ja)
*
|
2008-02-01 |
2009-08-06 |
Pharma Ip Limited Liability Intermediary Corporations |
新規ビアリール誘導体
|
|
EP2262370A4
(en)
*
|
2008-04-01 |
2011-08-31 |
Virobay Inc |
DIFLUOROUS COMPOUNDS AS A CYSTONE PROTEASE INHIBITOR
|
|
WO2009125861A1
(ja)
*
|
2008-04-09 |
2009-10-15 |
帝人ファーマ株式会社 |
システインプロテアーゼ阻害剤
|
|
US20110065800A1
(en)
*
|
2008-05-14 |
2011-03-17 |
Haihong Fan |
Formulations for cathepsin k inhibitors
|
|
CA2758210C
(en)
*
|
2009-04-20 |
2017-08-29 |
F. Hoffmann-La Roche Ag |
Proline derivatives as cathepsin inhibitors
|
|
US8324417B2
(en)
*
|
2009-08-19 |
2012-12-04 |
Virobay, Inc. |
Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
|
|
US9051304B2
(en)
*
|
2009-12-22 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Carboxamide compounds and their use as calpain inhibitors V
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
EP2681188A4
(en)
*
|
2011-03-02 |
2015-04-15 |
Merck Sharp & Dohme |
amidation
|
|
US8680152B2
(en)
|
2011-05-02 |
2014-03-25 |
Virobay, Inc. |
Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
|
|
WO2012156311A1
(en)
|
2011-05-16 |
2012-11-22 |
Bayer Intellectual Property Gmbh |
Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
|
|
EP2802658A2
(en)
|
2012-01-09 |
2014-11-19 |
Novartis AG |
Rnai agents to treat beta-catenin related diseases
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9528011B2
(en)
|
2013-01-11 |
2016-12-27 |
Ceraloc Innovation Ab |
Digital binder and powder print
|
|
ES2671516T3
(es)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
|
|
ES2753386T3
(es)
|
2013-03-13 |
2020-04-08 |
Forma Therapeutics Inc |
Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2014184380A1
(en)
|
2013-05-16 |
2014-11-20 |
Sandoz Ag |
Tablet with increased drug load of odanacatib
|
|
EP2808012A1
(en)
|
2013-05-29 |
2014-12-03 |
ratiopharm GmbH |
Method for producing dosage form comprising odanacatib
|
|
WO2014199644A1
(ja)
|
2013-06-14 |
2014-12-18 |
生化学工業株式会社 |
α－オキソアシルアミノカプロラクタム誘導体
|
|
WO2014199645A1
(ja)
|
2013-06-14 |
2014-12-18 |
生化学工業株式会社 |
α－オキソアシルアミノカプロラクタム体
|
|
WO2015006177A1
(en)
*
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Formulations for cathepsin k inhibitors with vitamin d
|
|
CN105593230B
(zh)
*
|
2013-10-08 |
2018-07-06 |
默沙东公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CZ2014941A3
(cs)
|
2014-12-19 |
2016-06-29 |
Zentiva, K.S. |
Příprava vysoce čistého intermediátu pro syntézu Odanacatibu
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
WO2016203405A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
EP3342765B1
(en)
*
|
2015-08-29 |
2021-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Cathepsin k inhibitor and application thereof
|
|
WO2017089389A1
(en)
*
|
2015-11-26 |
2017-06-01 |
F. Hoffmann-La Roche Ag |
Trypanosomes inhibitors
|
|
CN106866502B
(zh)
*
|
2015-12-10 |
2020-10-09 |
广东东阳光药业有限公司 |
组织蛋白酶k抑制剂及其用途
|
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
|
WO2017216706A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
SI3575284T1
(sl)
*
|
2017-01-24 |
2021-11-30 |
Astellas Pharma Inc. |
Spojina fenildifluorometil substituiranega prolinamida
|
|
KR101916396B1
(ko)
|
2017-02-20 |
2018-11-08 |
서울대학교 산학협력단 |
항암제 또는 항균제로 사용될 수 있는 단백질분해효소 저해제
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
|
|
NL2020021B1
(en)
*
|
2017-12-05 |
2019-06-13 |
Academisch Ziekenhuis Leiden |
Cathepsin inhibitors
|
|
EP4046987B1
(en)
*
|
2017-12-05 |
2025-08-27 |
Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) |
Cathepsin inhibitors
|
|
KR102709682B1
(ko)
|
2018-03-28 |
2024-09-25 |
한림제약(주) |
2-시아노피리미딘-4-일 카르바메이트 혹은 유레아 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
CR20210175A
(es)
|
2018-09-18 |
2021-06-01 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
|
|
JP2022502495A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
|
|
US20220041613A1
(en)
|
2018-09-25 |
2022-02-10 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
IL305106B2
(en)
|
2018-09-29 |
2025-08-01 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
WO2020201572A1
(en)
|
2019-04-05 |
2020-10-08 |
Université De Bretagne Occidentale |
Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
AU2020328598A1
(en)
|
2019-08-15 |
2022-03-03 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
CN114539111A
(zh)
*
|
2020-11-19 |
2022-05-27 |
深圳信立泰药业股份有限公司 |
奥当卡替的盐及其制备方法和医药用途
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202317589A
(zh)
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為ｋｒａｓ抑制劑的伸烷基衍生物
|
|
CN119053595A
(zh)
|
2022-03-28 |
2024-11-29 |
尼坎治疗公司 |
作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物
|
|
CN119790053A
(zh)
|
2022-06-08 |
2025-04-08 |
霖康疗法公司 |
作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
|
|
AU2023375457A1
(en)
|
2022-11-11 |
2025-05-01 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
TW202527955A
(zh)
|
2023-11-27 |
2025-07-16 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|